DIAGNOS Announces its New Mission in Healthcare after its Divestiture from the Mining Industry

/EINPresswire.com/ — BROSSARD, QUEBEC–(Marketwired – May 31, 2017) – Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX VENTURE:ADK), a leader in early detection of critical health issues through the use of Artificial Intelligence, announces its new mission in healthcare.

Further to the news release dated May 17th, 2017, the Corporation has received a certificate for 8,000,000 common shares of Majescor Resources Inc. pursuant to the sale of the assets from its mining division initially announced on March 15th, 2017. From now on, the Corporation’s will solely focus on Healthcare with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis).

AI gets real!

AI in healthcare aims to improve patient outcomes by assisting healthcare practitioners in using medical knowledge dramatically. The AI market for healthcare applications is expected to achieve rapid adoption globally, with a compound annual growth rate of 42 percent until 2021. By 2020, chronic conditions such as cancer and diabetes are expected to be diagnosed in minutes using cognitive systems. By 2025, AI systems are expected to be implemented in 90 percent of the US and 60 percent of the global hospitals and insurance companies (source JP Morgan).

Today DIAGNOS helps take care of more than 135,000 patients. We are using AI in more than 15 countries to help detect anomalies in retina due to diabetic retinopathy. We are making a difference today and we are preventing blindness. DIAGNOS CARA system combines the latest in advanced retinal imaging with clinical interpretation of the images. The painless, non-invasive procedure takes minutes to complete, and gives a visual representation of the states of one’s diabetes.

As per DIAGNOS’s President, Andre Larente, “Early diagnosis allows doctor to prescribe treatments earlier. With our CARA solution, we intend to diminish the highly repetitive work in screening a large group of patients and empower doctor to spend more quality time in delivering care.”

About DIAGNOS

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC). CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real-time and has been approved by regulatory authorities including Health Canada, US Food and Drug Administration, the European Union and in Mexico.

Visit our new website at: http://www.diagnos.ca/.

This document contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publically update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release are expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Eurocontrol's Xenemetrix Receives SICPA Order

/EINPresswire.com/ — TORONTO, ONTARIO–(Marketwired – May 31, 2017) – Eurocontrol Technics Group Inc. (TSX VENTURE:EUO)(OTCQB:EUCTF) (“Eurocontrol” or the “Company”), a Canadian public company specializing in the acquisition, development and commercialization of innovative test and measurement technologies for industry with application systems focused on the energy security, semiconductor and precision agriculture sectors, announces that its wholly-owned subsidiary Xenemetrix Ltd. (“Xenemetrix”) has received an order for six ED-XRF Petromark™ analyzer units for revenue of approximately US$250,000 from SICPA.

The order of units is in support of a three year contract renewal that was awarded after a tender process. The renewal provides evidence that the Petromark™ marking solution is continuing to address and discourage fuel adulteration providing increased oil revenues. The Petromark™ fuel marking system functions as an “in-product tax stamp” that cannot be removed, altered or copied. The detection technology supplied by Xenemetrix is highly accurate and exploits advanced ED-XRF spectrometry techniques providing the sophisticated tool available to eliminate fraud in the oil sector. Xenemetrix has an exclusive long-term supply, maintenance and support agreement with SICPA to supply ED-XRF spectrometry equipment and services related to the oil and gas marking and monitoring field.

The problem of fuel adulteration and theft is widespread as demonstrated by a recent Infographic created by Visual Capital – http://www.eurocontrol.ca/index.php/about-us/global-black-market-for-oil.

Bruce Rowlands, Chairman and CEO stated, “We are pleased to receive this initial order and continue our support of SICPA and we look forward to additional equipment orders and in the case of new contracts, additional earn-out revenue as their efforts since acquiring our former fuel marking subsidiary come to fruition.”

About Eurocontrol Technics Group Inc.

Eurocontrol is a TSX Venture and OTCQB traded company that specializes in the acquisition, development and commercialization of innovative test and measurement technologies for industry with application technologies focused on the energy security, semiconductor and precision farming sectors based on Xenemetrix’s core technological platform of ED-XRF. Eurocontrol has three wholly owned subsidiaries, Xenemetrix Ltd., XwinSys Technology Development Ltd. and Croptimal Ltd. and an agreement with SICPA S.A. for semi-annual earn-out payments of 5% (minimum $9 million over six years) on revenues generated from the oil and gas marking and monitoring field relating to the sale of its former subsidiary Global Fluids International (GFI) S.A. Xenemetrix is a leading designer, manufacturer and marketer of ED-XRF systems, a technology that is the most accurate and economic method for determining the chemical composition of many types of materials, including the analysis of petroleum oils and fuel. Xenemetrix has an exclusive long-term supply, maintenance and support agreement with SICPA to supply Xenemetrix products and services related to the oil and gas marking and monitoring field. XwinSys has developed a patented, fully automated metrology system for the semiconductor industry that combines 2D and 3D image processing technology with Xenemetrix’s ED-XRF technology. Croptimal, is introducing a new mobile ED-XRF spectroscopic material analysis laboratory for the precision agriculture industry that could dramatically change agricultural testing methodology and increase crop yields.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Forward-Looking Statements: This press release contains forward-looking statements. More particularly, this press release contains statements. Forward-looking statements are frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. The forward-looking statements are based on certain key expectations and assumptions made by Eurocontrol. Although Eurocontrol believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because Eurocontrol can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. In addition to other risks that may affect the forward-looking statements in this press release are those set out in Eurocontrol’s management discussion and analysis of the financial condition and results of operations for the quarter ended March 31, 2017 which is available on the Corporation’s profile at www.sedar.com. The forward-looking statements contained in this press release are made as of the date hereof and Eurocontrol undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Nine Canadian Municipalities Win National Awards of Excellence

/EINPresswire.com/ — GATINEAU, QUEBEC–(Marketwired – May 31, 2017) – Nine Canadian municipalities have won national awards of excellence from the Canadian Association of Municipal Administrators (CAMA) in the areas of innovation, education and professional development. Presented during CAMA’s national in Gatineau, QC, the following municipalities and projects were recognized, based on their population size:

2017 CAMA Willis Award for Innovation

  • Town of Inuvik, NT – East Channel Water Treatment Plant
  • City of Waterloo, ON – Waterloo’s Own PickUpHub
  • City of Kitchener, ON – Digital Kitchener: Kitchener’s Approach to a Smart City

2017 CAMA Environment Award

  • Northern Sunrise County, AB – Fire Hall Solar Project
  • City of Fort St. John, BC – Micro Hydro Project
  • City of Markham, ON – Markham SMART Textile Diversion Strategy

2017 CAMA Professional Development Award

  • District of Squamish, BC – Hardwired for Leadership
  • Strathcona County, AB – Priority Based Business Planning and Budgeting
  • City of Coquitlam, BC – “Leading with Purpose” Leadership Development Program

About CAMA:

The Canadian Association of Municipal Administrators (CAMA) is a national, non-profit association open to all Chief Administrative Officers / City Managers and any person employed in a senior management position that reports directly to a CAO. With a membership of approximately 575 senior municipal employees, from all parts of Canada, CAMA collectively represents more than 70% of the nation’s population. www.camacam.ca

Petrolia Energy Increases Shareholders Equity By $2 Million

/EINPresswire.com/ — HOUSTON, TX–(Marketwired – May 31, 2017) – Petrolia Energy Corporation (OTCQB: BBLS) (“Petrolia” or the “Company”) an energy company that specializes in acquiring, remediating and reengineering existing oil fields, announced today that it has increased shareholders equity by $2,000,000 by negotiating the conversion of certain short-term and long-term debt into equity.

The 2016 purchase of the Slick Unit Dutcher Sands oilfield (“SUDS”), a 2,600-acre former SOHIO Petroleum discovery in Creek County, Oklahoma, resulted in a $1,000,000 short-term and $3 million long-term liability owed to the Seller, Jovian Petroleum Corporation (“Jovian”). Jovian has converted $2,000,000 of this liability into an equity position in Petrolia, which includes the issuance of 10,000,000 shares of common stock at $0.20 per share accompanied by 6,000,000 warrants @ $0.20 per share and 4,000,000 warrants @ $0.35 per share.

“This transaction will result in a positive adjustment to the Company’s Shareholder’s Equity by $2 million and significantly reduce the Company’s debt to equity ratio,” said Paul Deputy, Chief Financial Officer of Petrolia. “This clearly demonstrates Managements commitment to improving our shareholder value.”

Details of the debt conversion are available on Form 8K filed on May 31, 2017 with the Securities and Exchange Commission.

For additional information, please refer to Petrolia’s filings with the SEC, which can be accessed on our website at www.petroliaenergy.com.

About Petrolia Energy Corporation

Petrolia Energy Corporation is a Houston-based, oil exploration and production company. With operations in Texas, Oklahoma and New Mexico, the Company focuses on redeveloping existing oil fields in well-established oil rich regions of the U.S., employing industry-leading technologies to create added value.

Petrolia is committed to achieving its goals through conscientious partnership with the communities in which we operate and through operations that extend beyond regulatory requirements and embrace responsible environmental stewardship. We firmly believe we can maximize a field’s potential value for our shareholders and employees, while protecting the environment and enhancing local communities.

Forward-looking Statements

Certain information in this press release constitutes forward-looking statements within the meaning of applicable securities laws, including, but not limited to, statements regarding well production, use of proceeds, future drilling, operating expenses, and additional funding. Any statement that does not contain a historical fact may be deemed to be a forward-looking statement. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “should,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” or “continue,” the negative of such terms, or other comparable terminology, although not all forward-looking statements contain such identifying words.

Forward-looking statements are subject to a number of assumptions, risks, and uncertainties, many of which are beyond the Company’s control, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. Such assumptions, risks, and uncertainties include, among others, those associated with exploration activities, oil and gas production, marketing and transportation, costs of operations, loss of markets, volatility of oil and gas prices, reserve and future production estimates, environmental risks, competition, inability to access sufficient capital from internal and external sources, general economic conditions, litigation, and changes in regulation and legislation. Readers are cautioned that the foregoing list is not exhaustive.

Additional information on these and other factors that could affect Petrolia’s operations or financial results is available by contacting Petrolia. The forward-looking statements contained in this press release are made as of the date of this press release, and Petrolia does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events, or otherwise, except as expressly required by applicable law.

Petrolia Energy Corporation shares are traded on the OTC Exchange under the symbol BBLS.

Gazprom’s exports to Germany grow by 3 billion cubic meters since early 2017

Background

Uniper SE is a subsidiary of E.ON SE focused on power generation and global energy trading.

Gazprom and Uniper cooperate in gas supplies and transportation abroad and implement joint scientific & technical and social & cultural programs.

Nord Stream 2 is the construction project for a gas pipeline with the annual capacity of 55 billion cubic meters from Russia to Germany across the Baltic Sea. The project is implemented by Nord Stream 2 AG, where Gazprom is the sole shareholder. On April 24, 2017, Nord Stream 2 AG, ENGIE S.A., OMV AG, Royal Dutch Shell plc, Uniper SE, and Wintershall Holding GmbH signed the financing agreements for the Nord Stream 2 project.

In 2016, Gazprom’s gas supplies to Germany hit a record high of 49.8 billion cubic meters (a 10 per cent increase compared to 2015).

Aqua Metals Hosts First Analyst Visitor Day

ALAMEDA, Calif., May 31, 2017 (GLOBE NEWSWIRE) — Aqua Metals, Inc. (NASDAQ:AQMS), (“Aqua Metals” or the “Company”), which is commercializing a non-polluting electrochemical lead recycling technology called AquaRefining™, today successfully hosted its first analyst visitor day.
The analysts were given a tour of AquaRefinery 1, located in the Tahoe-Reno Industrial Complex (TRIC), led by Aqua Metals’ executive management team. Analysts were able to view the critical processes at the AquaRefinery as they happened, including: battery feedstock deliveries; battery breaking and separation; desulfurization and pre-AquaRefining digestion processes; AquaRefining on simultaneously running AquaRefining modules; and shipments of lead products to customers.Among the firms that attended the visitor day were analysts from Oppenheimer & Co. Inc., Euro Pacific Capital and National Securities Corporation. The day also included representation from Green Bank, which provided Aqua Metals with a $10 million loan in 2015 which is backed by a 90 percent loan guarantee from the U.S. Department of Agriculture (USDA).“It has been a busy few months for our team as we continue to pursue our production milestones and step ever closer to full output of AquaRefined lead at TRIC,” said Dr. Stephen R. Clarke, CEO and chairman of Aqua Metals. “We aim to be as transparent as possible while protecting our IP, as we expand our operations and collaborate with new partners.  This was a valuable opportunity to open our doors to the analyst community, providing a behind-the-scenes look at our process.”The Company expects all the analysts who attended the visitor day to update their coverage reports to reflect findings from the site visit in the coming days.   
AquaRefinery 1 is ramping towards a total production output of 120 metric tonnes of lead products per day by the end of 2017. Aqua Metals is currently also working on plans to build a second AquaRefinery and integrating AquaRefining into a to-be-named existing lead smelter with its strategic partner, Johnson Controls. Regular updates on scaling of production and other Aqua Metals news can be found on the Aqua Metals website (http://www.aquametals.com).
About Aqua Metals
Aqua Metals, Inc. (NASDAQ:AQMS) is reinventing lead recycling with its patent-pending AquaRefiningTM technology. Unlike smelting, AquaRefining is a room temperature, water-based process that is fundamentally non-polluting. These modular systems allow the Company to vastly reduce environmental impact and scale lead acid recycling production capacity both by building its own AquaRefineries and licensing the AquaRefining technology to partners. This meets growing demand for lead to power new applications including stop/start automobile batteries which complement the vehicle’s main battery, Internet data centers, alternative energy applications including solar, wind, and grid scale storage. Aqua Metals is based in Alameda, California, and has built its first recycling facility in Nevada’s Tahoe Reno Industrial Complex. To learn more, please visit www.aquametals.com.
Safe Harbor
This press release contains forwardlooking statements concerning Aqua Metals, Inc., the lead acid battery recycling industry, the future of lead acid battery recycling via traditional smelters, the Companys development of its commercial lead acid battery recycling facilities and the quality, efficiency and profitability of the Companys proposed lead acid battery recycling operations. Those forwardlooking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (1) the fact that the Company only recently commenced revenue producing operations, thus subjecting the Company to all of the risks inherent in a prerevenue startup; (2) risks related to Aqua Metals ability to raise sufficient capital, as and when needed, to develop and operate its recycling facilities; (3) changes in the federal, state and foreign laws regulating the recycling of lead acid batteries; (4) the Companys ability to protect its proprietary technology, trade secrets and knowhow and (5) those other risks disclosed in the section Risk Factors included in the Companys Annual Report on Form 10-K filed on March 2, 2017. Aqua Metals cautions readers not to place undue reliance on any forwardlooking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.
Aqua Metals Media Relations:
Antenna
Kimberly Setliff
415-977-1942

Aqua Metals Investor Relations:
MZ North America
Greg Falesnik
Managing Director
Main: 949-385-6449

www.mzgroup.us

Global Pharmaceutical Fine Chemicals Market 2017 Share, Trend, Segmentation and Forecast to 2022

Global Pharmaceutical Fine Chemicals market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer

PUNE, INDIA, May 31, 2017 /EINPresswire.com/ — Summary

Global Pharmaceutical Fine Chemicals market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including

Abbott
Akzo Nobel
Albemarle Corporation
AstraZeneca
BASF
Boehringer Ingelheim
Clariant
Eastman Chemical
Evonik Industries
GlaxoSmithKlein
Lonza Group
Merck and co.
Roche
Royal DSM
The Dow Chemical Company

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/1327201-global-pharmaceutical-fine-chemicals-market-research-report-2017

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Pharmaceutical Fine Chemicals in these regions, from 2012 to 2022 (forecast), covering
North America
Europe
China
Japan
Southeast Asia
India

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Big Molecules
Small Molecules

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Pharmaceutical Fine Chemicals for each application, including
Non Proprietary Drugs
Poprietary Drugs

At any Query @ https://www.wiseguyreports.com/enquiry/1327201-global-pharmaceutical-fine-chemicals-market-research-report-2017

Table of Contents

Global Pharmaceutical Fine Chemicals Market Research Report 2017
1 Pharmaceutical Fine Chemicals Market Overview
1.1 Product Overview and Scope of Pharmaceutical Fine Chemicals
1.2 Pharmaceutical Fine Chemicals Segment by Type (Product Category)
1.2.1 Global Pharmaceutical Fine Chemicals Production and CAGR (%) Comparison by Type (Product Category) (2012-2022)
1.2.2 Global Pharmaceutical Fine Chemicals Production Market Share by Type (Product Category) in 2016
1.2.3 Big Molecules
1.2.4 Small Molecules
1.3 Global Pharmaceutical Fine Chemicals Segment by Application
1.3.1 Pharmaceutical Fine Chemicals Consumption (Sales) Comparison by Application (2012-2022)
1.3.2 Non Proprietary Drugs
1.3.3 Poprietary Drugs
1.4 Global Pharmaceutical Fine Chemicals Market by Region (2012-2022)
1.4.1 Global Pharmaceutical Fine Chemicals Market Size (Value) and CAGR (%) Comparison by Region (2012-2022)
1.4.2 North America Status and Prospect (2012-2022)
1.4.3 Europe Status and Prospect (2012-2022)
1.4.4 China Status and Prospect (2012-2022)
1.4.5 Japan Status and Prospect (2012-2022)
1.4.6 Southeast Asia Status and Prospect (2012-2022)
1.4.7 India Status and Prospect (2012-2022)
1.5 Global Market Size (Value) of Pharmaceutical Fine Chemicals (2012-2022)
1.5.1 Global Pharmaceutical Fine Chemicals Revenue Status and Outlook (2012-2022)
1.5.2 Global Pharmaceutical Fine Chemicals Capacity, Production Status and Outlook (2012-2022)

7 Global Pharmaceutical Fine Chemicals Manufacturers Profiles/Analysis
7.1 Abbott
7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.1.2 Pharmaceutical Fine Chemicals Product Category, Application and Specification
7.1.2.1 Product A
7.1.2.2 Product B
7.1.3 Abbott Pharmaceutical Fine Chemicals Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.1.4 Main Business/Business Overview
7.2 Akzo Nobel
7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.2.2 Pharmaceutical Fine Chemicals Product Category, Application and Specification
7.2.2.1 Product A
7.2.2.2 Product B
7.2.3 Akzo Nobel Pharmaceutical Fine Chemicals Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.2.4 Main Business/Business Overview
7.3 Albemarle Corporation
7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.3.2 Pharmaceutical Fine Chemicals Product Category, Application and Specification
7.3.2.1 Product A
7.3.2.2 Product B
7.3.3 Albemarle Corporation Pharmaceutical Fine Chemicals Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.3.4 Main Business/Business Overview
7.4 AstraZeneca
7.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.4.2 Pharmaceutical Fine Chemicals Product Category, Application and Specification
7.4.2.1 Product A
7.4.2.2 Product B
7.4.3 AstraZeneca Pharmaceutical Fine Chemicals Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.4.4 Main Business/Business Overview
7.5 BASF
7.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.5.2 Pharmaceutical Fine Chemicals Product Category, Application and Specification
7.5.2.1 Product A
7.5.2.2 Product B
7.5.3 BASF Pharmaceutical Fine Chemicals Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.5.4 Main Business/Business Overview
7.6 Boehringer Ingelheim
7.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.6.2 Pharmaceutical Fine Chemicals Product Category, Application and Specification
7.6.2.1 Product A
7.6.2.2 Product B
7.6.3 Boehringer Ingelheim Pharmaceutical Fine Chemicals Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.6.4 Main Business/Business Overview
7.7 Clariant
7.7.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.7.2 Pharmaceutical Fine Chemicals Product Category, Application and Specification
7.7.2.1 Product A
7.7.2.2 Product B
7.7.3 Clariant Pharmaceutical Fine Chemicals Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.7.4 Main Business/Business Overview
7.8 Eastman Chemical
7.8.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.8.2 Pharmaceutical Fine Chemicals Product Category, Application and Specification
7.8.2.1 Product A
7.8.2.2 Product B
7.8.3 Eastman Chemical Pharmaceutical Fine Chemicals Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.8.4 Main Business/Business Overview
7.9 Evonik Industries
7.9.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.9.2 Pharmaceutical Fine Chemicals Product Category, Application and Specification
7.9.2.1 Product A
7.9.2.2 Product B
7.9.3 Evonik Industries Pharmaceutical Fine Chemicals Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.9.4 Main Business/Business Overview
7.10 GlaxoSmithKlein
7.10.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.10.2 Pharmaceutical Fine Chemicals Product Category, Application and Specification
7.10.2.1 Product A
7.10.2.2 Product B
7.10.3 GlaxoSmithKlein Pharmaceutical Fine Chemicals Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.10.4 Main Business/Business Overview
7.11 Lonza Group
7.12 Merck and co.
7.13 Roche
7.14 Royal DSM
7.15 The Dow Chemical Company

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1327201

Continued….

NORAH TRENT
Wise Guy Reports
+91 841 198 5042
email us here

Global Pharmaceutical Fine Chemicals Market 2017 Share, Trend, Segmentation and Forecast to 2022

Global Pharmaceutical Fine Chemicals market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer

PUNE, INDIA, May 31, 2017 /EINPresswire.com/ — Summary

Global Pharmaceutical Fine Chemicals market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including

Abbott
Akzo Nobel
Albemarle Corporation
AstraZeneca
BASF
Boehringer Ingelheim
Clariant
Eastman Chemical
Evonik Industries
GlaxoSmithKlein
Lonza Group
Merck and co.
Roche
Royal DSM
The Dow Chemical Company

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/1327201-global-pharmaceutical-fine-chemicals-market-research-report-2017

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Pharmaceutical Fine Chemicals in these regions, from 2012 to 2022 (forecast), covering
North America
Europe
China
Japan
Southeast Asia
India

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Big Molecules
Small Molecules

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Pharmaceutical Fine Chemicals for each application, including
Non Proprietary Drugs
Poprietary Drugs

At any Query @ https://www.wiseguyreports.com/enquiry/1327201-global-pharmaceutical-fine-chemicals-market-research-report-2017

Table of Contents

Global Pharmaceutical Fine Chemicals Market Research Report 2017
1 Pharmaceutical Fine Chemicals Market Overview
1.1 Product Overview and Scope of Pharmaceutical Fine Chemicals
1.2 Pharmaceutical Fine Chemicals Segment by Type (Product Category)
1.2.1 Global Pharmaceutical Fine Chemicals Production and CAGR (%) Comparison by Type (Product Category) (2012-2022)
1.2.2 Global Pharmaceutical Fine Chemicals Production Market Share by Type (Product Category) in 2016
1.2.3 Big Molecules
1.2.4 Small Molecules
1.3 Global Pharmaceutical Fine Chemicals Segment by Application
1.3.1 Pharmaceutical Fine Chemicals Consumption (Sales) Comparison by Application (2012-2022)
1.3.2 Non Proprietary Drugs
1.3.3 Poprietary Drugs
1.4 Global Pharmaceutical Fine Chemicals Market by Region (2012-2022)
1.4.1 Global Pharmaceutical Fine Chemicals Market Size (Value) and CAGR (%) Comparison by Region (2012-2022)
1.4.2 North America Status and Prospect (2012-2022)
1.4.3 Europe Status and Prospect (2012-2022)
1.4.4 China Status and Prospect (2012-2022)
1.4.5 Japan Status and Prospect (2012-2022)
1.4.6 Southeast Asia Status and Prospect (2012-2022)
1.4.7 India Status and Prospect (2012-2022)
1.5 Global Market Size (Value) of Pharmaceutical Fine Chemicals (2012-2022)
1.5.1 Global Pharmaceutical Fine Chemicals Revenue Status and Outlook (2012-2022)
1.5.2 Global Pharmaceutical Fine Chemicals Capacity, Production Status and Outlook (2012-2022)

7 Global Pharmaceutical Fine Chemicals Manufacturers Profiles/Analysis
7.1 Abbott
7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.1.2 Pharmaceutical Fine Chemicals Product Category, Application and Specification
7.1.2.1 Product A
7.1.2.2 Product B
7.1.3 Abbott Pharmaceutical Fine Chemicals Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.1.4 Main Business/Business Overview
7.2 Akzo Nobel
7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.2.2 Pharmaceutical Fine Chemicals Product Category, Application and Specification
7.2.2.1 Product A
7.2.2.2 Product B
7.2.3 Akzo Nobel Pharmaceutical Fine Chemicals Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.2.4 Main Business/Business Overview
7.3 Albemarle Corporation
7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.3.2 Pharmaceutical Fine Chemicals Product Category, Application and Specification
7.3.2.1 Product A
7.3.2.2 Product B
7.3.3 Albemarle Corporation Pharmaceutical Fine Chemicals Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.3.4 Main Business/Business Overview
7.4 AstraZeneca
7.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.4.2 Pharmaceutical Fine Chemicals Product Category, Application and Specification
7.4.2.1 Product A
7.4.2.2 Product B
7.4.3 AstraZeneca Pharmaceutical Fine Chemicals Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.4.4 Main Business/Business Overview
7.5 BASF
7.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.5.2 Pharmaceutical Fine Chemicals Product Category, Application and Specification
7.5.2.1 Product A
7.5.2.2 Product B
7.5.3 BASF Pharmaceutical Fine Chemicals Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.5.4 Main Business/Business Overview
7.6 Boehringer Ingelheim
7.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.6.2 Pharmaceutical Fine Chemicals Product Category, Application and Specification
7.6.2.1 Product A
7.6.2.2 Product B
7.6.3 Boehringer Ingelheim Pharmaceutical Fine Chemicals Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.6.4 Main Business/Business Overview
7.7 Clariant
7.7.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.7.2 Pharmaceutical Fine Chemicals Product Category, Application and Specification
7.7.2.1 Product A
7.7.2.2 Product B
7.7.3 Clariant Pharmaceutical Fine Chemicals Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.7.4 Main Business/Business Overview
7.8 Eastman Chemical
7.8.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.8.2 Pharmaceutical Fine Chemicals Product Category, Application and Specification
7.8.2.1 Product A
7.8.2.2 Product B
7.8.3 Eastman Chemical Pharmaceutical Fine Chemicals Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.8.4 Main Business/Business Overview
7.9 Evonik Industries
7.9.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.9.2 Pharmaceutical Fine Chemicals Product Category, Application and Specification
7.9.2.1 Product A
7.9.2.2 Product B
7.9.3 Evonik Industries Pharmaceutical Fine Chemicals Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.9.4 Main Business/Business Overview
7.10 GlaxoSmithKlein
7.10.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.10.2 Pharmaceutical Fine Chemicals Product Category, Application and Specification
7.10.2.1 Product A
7.10.2.2 Product B
7.10.3 GlaxoSmithKlein Pharmaceutical Fine Chemicals Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.10.4 Main Business/Business Overview
7.11 Lonza Group
7.12 Merck and co.
7.13 Roche
7.14 Royal DSM
7.15 The Dow Chemical Company

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1327201

Continued….

NORAH TRENT
Wise Guy Reports
+91 841 198 5042
email us here

Automated Trading 2017 Global Market Expected to Grow at CAGR 10.31% and Forecast to 2020

Automated Trading Market

WiseGuyReports.Com Publish a New Market Research Report On – “Automated Trading 2017 Global Market Expected to Grow at CAGR 10.31% and Forecast to 2020”.

PUNE, INDIA, May 31, 2017 /EINPresswire.com/ —

The analysts forecast the global automated trading market to grow at a CAGR of 10.31% during the period 2016-2020.

The automated trading systems are also referred to as algorithmic trading or mechanical trading systems where it allows the trader to establish specific rules for both trade entries and trade exits. They are generally programmed in a way so that they can be automatically executed through computer systems. The entry and exit in the trade is based on the moving average crossovers. Sometimes it also requires the understanding of the programming language that is specific to the user’s trading platform. The automated trading requires the use of software that is linked to a direct access broker and the specific rules that are written in the proprietary language in the platform. For instance, the TradeStation platform uses the Easy programming language.

Get a Sample Report @ https://www.wiseguyreports.com/sample-request/687163-global-automated-trading-market-2016-2020

For more information or any query mail at sales@wiseguyreports.com

Covered in this report

The report covers the present scenario and the growth prospects of the global automated trading market for 2016-2020. To calculate the market size, the report considers the net commission earned from automated trading platform providers in the Americas, APAC, and EMEA.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

The report, Global Automated Trading Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• Citadel
• KCG
• Optiver
• Two Sigma Investments

Other prominent vendors
• DRW Trading
• Flow Traders
• Hudson River Trading
• Jump Trading
• RSJ Algorithmic Trading
• Spot Trading
• Sun Trading
• Tower Research Capital
• Tradebot Systems
• Virtu Financial

Market driver
• Increased integration of financial markets
• For a full, detailed list, view our report

Market challenge
• Lack of awareness in automated trading
• For a full, detailed list, view our report

Market trend
• Advancements in technology
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Complete Report Details @ https://www.wiseguyreports.com/reports/687163-global-automated-trading-market-2016-2020

Table Of Contents – Major Key Points

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Countries covered
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights
• Automated trading overview
• Advantages of automated trading
• Disadvantages of automated trading
• Use of automated trading
• Basic life cycle in automated trading
• Benefits of automated trading

PART 05: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 06: Geographical segmentation
• Geographical segmentation
• Americas
• EMEA
• APAC

PART 07: Market drivers
• Higher demand for market surveillance
• Increased integration of financial markets
• Algorithmic imports in Asia

PART 08: Impact of drivers

PART 09: Market challenges
• Lack of awareness in automated trading
• Wider bid-ask spread in Asia
• Insufficient risk valuation capabilities, operational inefficiencies, and limited legal certainty

Continued…….

For more information or any query mail at sales@wiseguyreports.com

Buy 1-User PDF @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=687163

ABOUT US:
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of rmaket research reports under these categories and sub-categories.

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

Automated Trading 2017 Global Market Expected to Grow at CAGR 10.31% and Forecast to 2020

Automated Trading Market

WiseGuyReports.Com Publish a New Market Research Report On – “Automated Trading 2017 Global Market Expected to Grow at CAGR 10.31% and Forecast to 2020”.

PUNE, INDIA, May 31, 2017 /EINPresswire.com/ —

The analysts forecast the global automated trading market to grow at a CAGR of 10.31% during the period 2016-2020.

The automated trading systems are also referred to as algorithmic trading or mechanical trading systems where it allows the trader to establish specific rules for both trade entries and trade exits. They are generally programmed in a way so that they can be automatically executed through computer systems. The entry and exit in the trade is based on the moving average crossovers. Sometimes it also requires the understanding of the programming language that is specific to the user’s trading platform. The automated trading requires the use of software that is linked to a direct access broker and the specific rules that are written in the proprietary language in the platform. For instance, the TradeStation platform uses the Easy programming language.

Get a Sample Report @ https://www.wiseguyreports.com/sample-request/687163-global-automated-trading-market-2016-2020

For more information or any query mail at sales@wiseguyreports.com

Covered in this report

The report covers the present scenario and the growth prospects of the global automated trading market for 2016-2020. To calculate the market size, the report considers the net commission earned from automated trading platform providers in the Americas, APAC, and EMEA.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

The report, Global Automated Trading Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• Citadel
• KCG
• Optiver
• Two Sigma Investments

Other prominent vendors
• DRW Trading
• Flow Traders
• Hudson River Trading
• Jump Trading
• RSJ Algorithmic Trading
• Spot Trading
• Sun Trading
• Tower Research Capital
• Tradebot Systems
• Virtu Financial

Market driver
• Increased integration of financial markets
• For a full, detailed list, view our report

Market challenge
• Lack of awareness in automated trading
• For a full, detailed list, view our report

Market trend
• Advancements in technology
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Complete Report Details @ https://www.wiseguyreports.com/reports/687163-global-automated-trading-market-2016-2020

Table Of Contents – Major Key Points

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Countries covered
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights
• Automated trading overview
• Advantages of automated trading
• Disadvantages of automated trading
• Use of automated trading
• Basic life cycle in automated trading
• Benefits of automated trading

PART 05: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 06: Geographical segmentation
• Geographical segmentation
• Americas
• EMEA
• APAC

PART 07: Market drivers
• Higher demand for market surveillance
• Increased integration of financial markets
• Algorithmic imports in Asia

PART 08: Impact of drivers

PART 09: Market challenges
• Lack of awareness in automated trading
• Wider bid-ask spread in Asia
• Insufficient risk valuation capabilities, operational inefficiencies, and limited legal certainty

Continued…….

For more information or any query mail at sales@wiseguyreports.com

Buy 1-User PDF @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=687163

ABOUT US:
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of rmaket research reports under these categories and sub-categories.

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here